Veradermics, Inc (MANE) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$115.34

From 52W high−6.59%

Volume1.46M

Market cap$5.11B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$115.34

From 52W high

−6.59%

Volume

1.46M

Market cap

$5.11B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−44.1x

P/E (TTM)

—

RSI (14)

54.8

MomentumView details →

1D Return

+12.37%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−44.1x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

6.3x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−11.39%

ROA (TTM)

−11.22%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+12.37%

YTD Return

—

1Y Return

—

RSI (14)

54.8

vs 50D SMA

+9.90%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

70.53x

Quick Ratio

70.53x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.58

EPS Surprise

10.43%

Beats (12Q)

1/12

Next Q EPS Est

−$0.63

Avg Surprise (4Q)

10.43%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−92.68M

Op. CF (TTM)

−78.30M

Next earningsNov 10, 2026 →

Latest newsMore news →

Veradermics shares rose 6.98% to $116.42 on Monday after positive topline Phase 3 trial results were reported.10h ago

Veradermics announced positive topline results from Part A of its Phase 3 Study 304 evaluating oral VDPHL01 in more than 500 males with mild-to-moderate pattern hair loss.17h ago

Similar companies

PTC Therapeutics, Inc.PTCT Cogent Biosciences, Inc.COGT 博拓生物688767.SH Apellis Pharmaceuticals, Inc.APLS CK Life Sciences Int'l., (Holdings) Inc.00775.HK Oruka Therapeutics, Inc.ORKA Find similar companies →

Latest newsMore news →

Veradermics shares rose 6.98% to $116.42 on Monday after positive topline Phase 3 trial results were reported.10h ago Veradermics announced positive topline results from Part A of its Phase 3 Study 304 evaluating oral VDPHL01 in more than 500 males with mild-to-moderate pattern hair loss.17h ago Veradermics announced it will host an investor call and live webcast on October 19, 2026, at 8:00 a.m. ET to review Part A results from its Phase 3 Study 304 of VDPHL01.1d ago